Offer your patients access to advanced cancer screening support.
OmniHealth Africa works with healthcare providers to make OncoVeryx available through a clinically responsible pathway.
Clinical overview
OncoVeryx is a qualitative in-vitro diagnostic test developed by PredOmix. It profiles serum metabolites from a peripheral blood sample using liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS), followed by a proprietary deep-learning algorithm to identify metabolite signatures associated with cancer. When a cancer-associated signature is detected, the software also indicates likely tissue-of-origin possibilities to support follow-up. PredOmix reports high sensitivity across clinical stages I to IV, including early-stage and asymptomatic disease. The test was not evaluated for the detection of pre-cancerous (Stage 0) lesions.
Intended use
OncoVeryx is intended as an adjunct to routine clinical evaluation, to support healthcare professionals in deciding whether further investigation is warranted. It is designed to complement, not replace, established screening and diagnostic procedures. Results must be interpreted by a healthcare professional in the context of the patient’s medical history, signs and symptoms.
Limitations
- Not diagnostic
- Does not detect all cancers
- Positive results require clinical evaluation
- Negative results do not rule out cancer
- False positives and false negatives can occur
- Interpret alongside history, signs and symptoms
Positive, negative and invalid categories.
Cancer-associated signal detected
This may indicate the presence of cancer. The result does not confirm cancer. Further clinical evaluation is required, and your healthcare professional will refer you for further tests to confirm whether cancer is present.
No cancer-associated signal detected
This does not rule out cancer. Continue routine screening and medical advice from your healthcare provider.
Invalid
A fresh sample may be required if sample quality or quantity is insufficient for reliable analysis.
Follow-up principles
Follow-up is determined by the healthcare provider based on the result and the full clinical picture. Where a cancer-associated signature is detected, further clinical evaluation is required and may include imaging, specialist referral, laboratory testing or other diagnostic procedures. A negative result does not remove the need for routine, recommended screening.
A clear ordering and follow-up workflow.
- 01
Register interest
Submit the healthcare provider form to begin the onboarding conversation.
- 02
Receive onboarding material
Our team shares clinical and process guidance for your practice.
- 03
Confirm patient suitability
You assess whether the test is appropriate for a given patient.
- 04
Refer or order the test
Initiate the pathway through the approved ordering process.
- 05
Patient completes blood draw
Collection is completed by an approved provider or collection partner.
- 06
Results returned through approved pathway
Results are delivered through the appropriate medical channel.
- 07
Advise next steps
You guide follow-up based on the result and the clinical picture.
Screening is not diagnosis
OncoVeryx does not confirm cancer and does not rule out all cancers. False positive and false negative results can occur. Continue with routine cancer screening recommended by your healthcare provider.
Register as a healthcare provider.
Tell us about your practice and area of interest. Our team will follow up with onboarding information and process guidance.